Showing 34,893 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

PrEP

What People are Saying About Approval Of PrEP in Canada

Editor's pick
Positive Lite
1 March 2016
Finance & funding

Investing in prevention: is it cost-effective?

Editor's pick
Public Health England
1 March 2016
Conference announcements & declarations

Really Rapid Review — CROI 2016, Boston

Editor's pick
NEJM Journal Watch
1 March 2016
PrEP

Canada Approves Drug That Stops HIV Transmission, but It’s Still Really Expensive

Editor's pick
Vice
29 February 2016
The search for a cure

Experimental TLR7 agonist suppresses HIV-like virus in monkeys after ART interruption

News
29 February 2016
Epidemiology

Your lifetime risk of HIV by race, state and sexual preference — in four simple charts

Editor's pick
Washington Post
29 February 2016
Access to healthcare

His Job Is to Sell a $1,000 Pill for $10 Without Losing Money

Editor's pick
Bloomberg
29 February 2016
Cancer

Study does not support routine HPV quadrivalent vaccination to protect against anal cancer in older people living with HIV

News
29 February 2016
PrEP science

‘On-demand’ rectal microbicide gel has reasonable tolerability and acceptability – daily less so

News
28 February 2016
Treatment outcomes & life expectancy

Life expectancy in HIV-positive people in the US still lags 13 years behind HIV-negative people

News
28 February 2016
Global health targets

Option B+ has enabled Malawi to make significant progress towards 90-90-90

News
27 February 2016
PrEP

Condom use in French PrEP trial: half only used PrEP, a quarter used condoms and PrEP, one in six used neither

News
26 February 2016
New & experimental HIV treatments

European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV

Editor's pick
Gilead press release
26 February 2016
Finance & funding

Uganda risks losing Global Fund grants

Editor's pick
Key Correspondents
26 February 2016
People & personal stories

John Gagnon, Sociologist Who Explored Human Sexuality, Dies at 84

Editor's pick
New York Times
26 February 2016
Pharmaceutical industry

HIV unit emerges as 'critical' driver of GSK growth

Editor's pick
Financial Times
26 February 2016
TB treatment

Empirical TB treatment comes up short again

News
26 February 2016
Transmission & prevention

Modern HIV Prevention: What’s Next For Women?

Editor's pick
International AIDS Society
26 February 2016
Hepatitis C treatment

Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low

News
26 February 2016
People & personal stories

Interview with PrEP Warrior Damon L. Jacobs

Editor's pick
HIV Smart
26 February 2016
Cardiovascular disease

Cardiovascular Risk Tools for HIV Go Head-to-Head in Large U.S. Study

Editor's pick
The Body Pro
26 February 2016
Neurological & cognitive problems

Antidepressant May Improve Cognitive Symptoms in People with HIV

Editor's pick
Hopkins Medicine
26 February 2016
The search for a cure

Immunotherapy agent can disrupt viral reservoir in SIV-infected monkeys

Editor's pick
Emory Health Sciences
26 February 2016
The search for a cure

Sangamo BioSciences Presents Phase 2 Immunological Data from SB-728-T ZFP Therapeutic® HIV Program at CROI 2016

Editor's pick
Sangamo Biosciences press release
26 February 2016